Concepedia

Tina Guthrie

TG

5

Publications

398

Citations

5

H-Index

2004

Active since

Affiliations

Wayne State University(Current)

GlaxoSmithKline (United States)

The Barbara Ann Karmanos Cancer Institute

Cytokinetics (United States)

Sarah Cannon

Tina Guthrie is an author at Wayne State University specializing in cancer therapeutics, cancer research, and medicine.

Top concepts

Publications per year

2004–2012

5

Publications

5

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Ian E. Krop, Tim Demuth, Tina Guthrie et al. · Journal of Clinical Oncology · 2012 · 314 citations · Full text

Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days

Howard A. Burris, Patricia LoRusso, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2004 · 29 citations

, , +14

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study

Patricia LoRusso, Anthony F. Shields, Shirish M. Gadgeel et al. · Investigational New Drugs · 2010 · 20 citations

, , +6

A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.

Cristian Moldovan, Jean‐Charles Soria, P. LoRusso et al. · Journal of Clinical Oncology · 2010 · 20 citations

, , +18

Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days

H. A. Burris, P. LoRusso, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2004 · 15 citations

, , +14

Rows per page

1–5 of 5